4basebio
Tejaswini .B.M has a diverse professional background in the biotechnology and life sciences sectors, currently serving as the Template Generation Team Lead and Scientist III in Gene Expression at 4basebio since February 2022. Prior experience includes roles as a Genetic Technologist at Oncologica UK and a Marketing Executive at Prescient Technologies, where involvement included attending the International Security Expo. Tejaswini's earlier positions featured contributions as a Barista at SSP Group Plc., a Project Intern for ChangeMakers Network at SETsquared Partnership, and casual fundraising for the University of Bath. Further internship experiences include training in biotechnology and research techniques at various organizations, with a solid academic foundation in Molecular Bioscience from the University of Bath and a Bachelor’s in Biotechnology from Acharya College.
4basebio
4basebio is enabling next generation cell and gene therapies and vaccines with its technologies and solutions. We are able to design, manufacture and supply application-specific synthetic DNA or mRNA as well as targeted non-viral vectors for the delivery of nucleic acid payloads. Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmids and other DNA technologies. We currently offer four DNA construct types, each ideally suited for use in viral and non-viral vector applications, genome editing, vaccines and therapeutics, and DNA vaccine applications, respectively. Our proprietary non-viral delivery system, Hermes™, is a nanoparticle vector that can be customised to target cells or tissues of interest for a range of applications. This combines the safety and efficiency of lipid-based nanoparticles (LNPs) with the specificity of a targeting system, addressing the shortcoming associated with both viral vectors and non-targeted LNPs.